Chemo bead treatment with liver infusion for colorectal cancer spread
Part of Cancer clinical trials.
This trial compares two treatments for colorectal cancer that has spread to the liver: using tiny beads that deliver chemo directly to the tumor plus a liver infusion, versus the liver infusion alone. It aims to see which approach is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have colorectal cancer that has spread to your liver
- You have not had surgery to remove the liver tumors
- You have at least one tumor that can be measured on a scan
- Your liver function is at least moderately good (Child-Pugh A or B)
- You are able to take care of yourself (ECOG performance status 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a treatment called DEBIRI (tiny beads delivering chemo directly to the liver) plus standard chemotherapy works better than chemotherapy alone for colorectal cancer that has spread to the liver and can't be fully removed by surgery.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.